ALOPECIA AREATA

This study tests two doses (50 mg and 100 mg) of the daily pill ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss. Participants are randomly assigned to one of the two doses, and results are compared to data …

This study tests an experimental drug called rezpegaldesleukin for adults with severe to very severe alopecia areata, a condition causing significant hair loss. About 94 participants will receive either the drug or a placebo to see if it helps regrow hair over 36 weeks, with an o…

This study tests an experimental drug called amlitelimab, given as a shot under the skin, for adults with severe alopecia areata—a condition causing major hair loss on the scalp. About 166 participants will receive either the drug or a placebo for 36 weeks to see if it helps hair…

This study tests a new drug called bempikibart (ADX-914) for people with severe alopecia areata, a condition that causes large patches of hair loss on the scalp. The trial has two parts: first, a placebo-controlled phase to see if the drug works, and second, an open-label phase w…

This study follows 487 people with alopecia areata who are taking Litfulo capsules for the first time. Researchers want to confirm the drug's safety and how well it works in everyday use, not just in controlled trials. They will track side effects and measure hair regrowth using …

This early-phase study tests a new drug called DR-01 in adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. About 81 participants will receive the drug,…

This study compares two treatments for alopecia areata, a condition causing patchy hair loss. One group gets microneedling alone, the other gets microneedling plus vitamin D3 cream. Researchers will see if adding vitamin D helps more people achieve full hair regrowth over 3 month…

This study looks at the long-term safety and effectiveness of a drug called CTP-543 for adults with moderate to severe alopecia areata, a condition that causes patchy hair loss. About 1,000 people who already completed 24 weeks of treatment in a prior CTP-543 trial will continue …

This study is creating a large registry of up to 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants over time to see how treatments work in everyday medical practice and track any side effects. T…

This study reviews medical records of about 300 people in the US with severe alopecia areata (an autoimmune disease causing hair loss) who started taking the drug ritlecitinib. Researchers want to see how effective the drug is in real-world settings, not just in controlled trials…

This observational study examines whether blood levels of two markers (VEGF-A and VCAM-1) differ between people with alopecia areata and healthy individuals. Researchers will also check for tiny blood vessel changes in the nailfolds and link them to hair loss severity. About 90 a…